Donor-Derived Cell-Free DNA: What’s the Hype?

White paper: dd-cfDNA testing for post-transplant monitoring

Despite significant advances in transplantation, long-term graft survival has largely plateaued over the past two decades. Traditional post-transplant monitoring methods, such as serum creatinine and donor-specific antibody (DSA) testing, often identify allograft injury only after irreversible damage has begun, limiting opportunities for early intervention.

Emerging evidence suggests that donor-derived cell-free DNA (dd-cfDNA) has the potential to transform post-transplant monitoring. As a minimally invasive biomarker of allograft injury, dd-cfDNA can detect signs of rejection earlier than conventional methods, supporting more timely clinical decision-making, personalised immunosuppression and, in some cases, reducing the need for unnecessary biopsies.

In this white paper, we explore the growing body of clinical evidence supporting dd-cfDNA monitoring, including international consensus recommendations, published studies demonstrating its clinical utility, and the role of next-generation sequencing (NGS) in delivering highly sensitive, accurate testing. We also examine how the One Lambda Devyser Accept cfDNA assay is helping laboratories implement streamlined, high-performance dd-cfDNA testing for post-transplant monitoring.

Download the white paper to discover:

• Why current post-transplant monitoring strategies may detect graft injury too late.
• The clinical evidence supporting dd-cfDNA as an early biomarker of allograft injury.
• International guidance from ASTS and ESOT on the use of dd-cfDNA monitoring.
• How NGS-based dd-cfDNA testing supports earlier intervention and personalised patient management.
• The features and benefits of the One Lambda Devyser Accept cfDNA workflow for transplant laboratories.

Fill in this short form to receive your free copy of the white paper via email, and discover how dd-cfDNA monitoring is shaping the future of post-transplant care.